Perrigo EBIT Margin 2010-2025 | PRGO
Current and historical EBIT (Earnings Before Interest & Taxes) margin for Perrigo (PRGO) over the last 10 years. The current EBIT profit margin for Perrigo as of June 30, 2025 is .
| Perrigo EBIT Margin Historical Data | |||
|---|---|---|---|
| Date | TTM Revenue | TTM EBIT | EBIT Margin |
| 2025-06-30 | $4.33B | $0.29B | 6.61% |
| 2025-03-31 | $4.34B | $0.21B | 4.94% |
| 2024-12-31 | $4.37B | $0.11B | 2.56% |
| 2024-09-30 | $4.39B | $-0.02B | -0.41% |
| 2024-06-30 | $4.43B | $-0.04B | -0.81% |
| 2024-03-31 | $4.56B | $0.05B | 1.05% |
| 2023-12-31 | $4.66B | $0.15B | 3.24% |
| 2023-09-30 | $4.65B | $0.20B | 4.25% |
| 2023-06-30 | $4.63B | $0.17B | 3.65% |
| 2023-03-31 | $4.56B | $0.11B | 2.30% |
| 2022-12-31 | $4.45B | $0.08B | 1.77% |
| 2022-09-30 | $4.40B | $0.10B | 2.16% |
| 2022-06-30 | $4.35B | $0.50B | 11.51% |
| 2022-03-31 | $4.20B | $0.38B | 9.06% |
| 2021-12-31 | $4.14B | $0.41B | 9.91% |
| 2021-09-30 | $4.09B | $0.40B | 9.81% |
| 2021-06-30 | $4.05B | $0.04B | 1.04% |
| 2021-03-31 | $4.02B | $0.23B | 5.75% |
| 2020-12-31 | $4.09B | $0.27B | 6.51% |
| 2020-09-30 | $3.39B | $0.19B | 5.63% |
| 2020-06-30 | $3.58B | $0.17B | 4.64% |
| 2020-03-31 | $3.78B | $0.16B | 4.18% |
| 2019-12-31 | $3.87B | $0.17B | 4.50% |
| 2019-09-30 | $4.71B | $0.32B | 6.77% |
| 2019-06-30 | $4.65B | $0.14B | 3.07% |
| 2019-03-31 | $4.69B | $0.18B | 3.90% |
| 2018-12-31 | $4.73B | $0.24B | 5.01% |
| 2018-09-30 | $4.82B | $0.29B | 5.98% |
| 2018-06-30 | $4.92B | $0.57B | 11.63% |
| 2018-03-31 | $4.97B | $0.63B | 12.60% |
| 2017-12-31 | $4.95B | $0.60B | 12.11% |
| 2017-09-30 | $4.99B | $-0.05B | -0.90% |
| 2017-06-30 | $5.03B | $-1.68B | -33.33% |
| 2017-03-31 | $5.13B | $-1.64B | -31.96% |
| 2016-12-31 | $5.28B | $-2.00B | -37.87% |
| 2016-09-30 | $2.93B | $-2.01B | -68.50% |
| 2016-06-30 | $2.94B | $-0.36B | -12.32% |
| 2015-12-31 | $1.22B | $-0.13B | -10.27% |
| 2015-09-30 | $3.31B | $0.37B | 11.02% |
| 2014-12-31 | $3.03B | $0.24B | 7.93% |
| 2014-09-30 | $2.94B | $0.24B | 8.18% |
| 2013-12-31 | $2.83B | $0.36B | 12.68% |
| 2013-09-30 | $2.74B | $0.36B | 13.12% |
| 2012-12-31 | $2.43B | $0.30B | 12.46% |
| 2012-09-30 | $2.39B | $0.30B | 12.70% |
| 2011-12-31 | $2.26B | $0.23B | 9.98% |
| 2011-09-30 | $2.14B | $0.23B | 10.54% |
| 2010-12-31 | $1.90B | $0.20B | 10.60% |
| 2010-09-30 | $1.76B | $0.20B | 11.41% |
| 2009-12-31 | $1.62B | $0.16B | 9.78% |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Products Manufacturing | $3.272B | $4.373B |
| Perrigo Co. plc, with a diversified revenue stream, sells infant formulas for the store brand market, generic extended topical prescription (Rx) products and specialty pharmaceutical drugs. It's focusing on self-care products as part of its transformation into a self-care company from a healthcare company. The company divested its Rx segment to Altaris Capital Partners. The company completed its transformation to a consumer self-care company by reconfiguring the portfolio through the divestiture of RX business. Currently, the company has 2 reporting segments. Consumer Self Care Americas (CSCA): The segment comprises the U.S., Mexico and Canada CHC business, including OTC, contract manufacturing, infant formula and animal health categories. Consumer Self Care International?(CSCI): The segment comprises the branded consumer healthcare (BCH) segment mainly in Europe and the company's consumer-focused businesses in the UK and Australia. This segment includes UK liquids licensed products business. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Abbott Laboratories (ABT) | United States | $229.514B | 26.91 |
| Boston Scientific (BSX) | United States | $155.747B | 37.14 |
| Stryker (SYK) | United States | $149.436B | 30.42 |
| EssilorLuxottica (ESLOY) | France | $144.168B | 0.00 |
| Medtronic (MDT) | Ireland | $117.977B | 16.64 |
| Lonza Group Ag (LZAGY) | Switzerland | $49.715B | 0.00 |
| Haleon (HLN) | United Kingdom | $43.412B | 24.82 |
| ResMed (RMD) | United States | $41.845B | 29.93 |
| GE HealthCare Technologies (GEHC) | United States | $34.055B | 16.01 |
| Agilent Technologies (A) | United States | $33.846B | 22.07 |
| Koninklijke Philips (PHG) | Netherlands | $26.577B | 17.58 |
| Terumo (TRUMY) | Japan | $26.206B | 31.05 |
| Insulet (PODD) | United States | $23.159B | 77.59 |
| Zimmer Biomet Holdings (ZBH) | United States | $21.260B | 13.53 |
| Smith & Nephew SNATS (SNN) | United Kingdom | $16.271B | 0.00 |
| Baxter (BAX) | United States | $12.615B | 9.75 |
| Sunny Optical Technology (SNPTF) | China | $10.800B | 0.00 |
| Demant (WILYY) | Denmark | $8.121B | 0.00 |
| Bio-Rad Laboratories (BIO) | United States | $8.048B | 29.56 |
| Lantheus Holdings (LNTH) | United States | $3.819B | 10.32 |
| Envista Holdings (NVST) | United States | $3.510B | 24.56 |
| Shandong Weigao Medical Polymer (SHWGF) | China | $3.459B | 0.00 |
| Prestige Consumer Healthcare (PBH) | United States | $3.231B | 14.34 |
| ICU Medical (ICUI) | United States | $3.106B | 21.15 |
| Haemonetics (HAE) | United States | $2.661B | 11.88 |
| LeMaitre Vascular (LMAT) | United States | $2.209B | 47.38 |
| Acuren (TIC) | United States | $2.126B | 0.00 |
| Curaleaf Holdings (CURLF) | Canada | $2.005B | 0.00 |
| AtriCure (ATRC) | United States | $1.881B | 0.00 |
| QuidelOrtho (QDEL) | United States | $1.877B | 11.82 |
| Green Thumb Industries (GTBIF) | United States | $1.869B | 80.25 |
| Tilray Brands (TLRY) | Canada | $1.530B | 0.00 |
| Phibro Animal Health (PAHC) | United States | $1.295B | 16.55 |
| AdaptHealth (AHCO) | United States | $1.249B | 17.75 |
| BioLife Solutions (BLFS) | United States | $1.229B | 2565.00 |
| Neogen (NEOG) | United States | $1.216B | 19.31 |
| InMode (INMD) | Israel | $0.921B | 8.52 |
| Kestra Medical Technologies (KMTS) | United States | $0.910B | 0.00 |
| Valneva SE (VALN) | France | $0.802B | 0.00 |
| Cresco Labs (CRLBF) | United States | $0.648B | 0.00 |
| SNDL (SNDL) | Canada | $0.631B | 0.00 |
| Maravai LifeSciences Holdings (MRVI) | United States | $0.613B | 0.00 |
| Verano Holdings (VRNOF) | United States | $0.593B | 0.00 |
| ZimVie (ZIMV) | United States | $0.535B | 20.61 |
| Surmodics (SRDX) | United States | $0.505B | 0.00 |
| Evolus (EOLS) | United States | $0.481B | 0.00 |
| VAREX IMAGING (VREX) | United States | $0.473B | 16.29 |
| CeriBell (CBLL) | United States | $0.419B | 0.00 |
| Owens & Minor (OMI) | United States | $0.396B | 3.51 |
| Sanuwave Health (SNWV) | United States | $0.366B | 0.00 |
| Canopy Growth (CGC) | Canada | $0.345B | 0.00 |
| TerrAscend (TSNDF) | Canada | $0.331B | 0.00 |
| SEMPERIT AG HLD (SEIGY) | Austria | $0.317B | 0.00 |
| Capricor Therapeutics (CAPR) | United States | $0.302B | 0.00 |
| Omeros (OMER) | United States | $0.296B | 0.00 |
| Aurora Cannabis (ACB) | Canada | $0.295B | 0.00 |
| Sanara MedTech (SMTI) | United States | $0.293B | 0.00 |
| Brainsway (BWAY) | Israel | $0.290B | 59.08 |
| High Tide (HITI) | Canada | $0.283B | 0.00 |
| Viemed Healthcare (VMD) | United States | $0.275B | 20.85 |
| TriSalus Life Sciences (TLSI) | United States | $0.246B | 0.00 |
| Cerus (CERS) | United States | $0.245B | 0.00 |
| Vireo Growth (VREOF) | United States | $0.243B | 0.00 |
| OraSure Technologies (OSUR) | United States | $0.230B | 0.00 |
| Organigram Global (OGI) | Canada | $0.219B | 0.00 |
| Quanterix (QTRX) | United States | $0.217B | 0.00 |
| Exagen (XGN) | United States | $0.217B | 0.00 |
| Utah Medical Products (UTMD) | United States | $0.193B | 16.13 |
| FitLife Brands (FTLF) | United States | $0.171B | 21.05 |
| Biote (BTMD) | United States | $0.160B | 5.30 |
| Jushi Holdings (JUSHF) | United States | $0.142B | 0.00 |
| Jin Medical (ZJYL) | China | $0.133B | 0.00 |
| Quipt Home Medical (QIPT) | United States | $0.113B | 0.00 |
| MacroGenics (MGNX) | United States | $0.104B | 0.00 |
| Fonar (FONR) | United States | $0.095B | 12.31 |
| Oramed Pharmaceuticals (ORMP) | United States | $0.089B | 0.00 |
| Apyx Medical (APYX) | United States | $0.078B | 0.00 |
| Agape ATP (ATPC) | $0.066B | 0.00 | |
| Safety Shot (SHOT) | United States | $0.066B | 0.00 |
| Cytosorbents (CTSO) | United States | $0.057B | 0.00 |
| ImmuCell (ICCC) | United States | $0.055B | 32.03 |
| Veru (VERU) | United States | $0.051B | 0.00 |
| Zynex (ZYXI) | United States | $0.051B | 0.00 |
| Rockwell Medical (RMTI) | United States | $0.045B | 0.00 |
| Nephros (NEPH) | United States | $0.044B | 34.92 |
| Modular Medical (MODD) | United States | $0.042B | 0.00 |
| United-Guardian (UG) | United States | $0.037B | 14.36 |
| Trinity Biotech (TRIB) | Ireland | $0.028B | 0.00 |
| Senestech (SNES) | United States | $0.023B | 0.00 |
| INLIF (INLF) | $0.018B | 0.00 | |
| Allurion Technologies (ALUR) | United States | $0.017B | 0.00 |
| Cellectar Biosciences (CLRB) | United States | $0.015B | 0.00 |
| Meihua Medical Technologies (MHUA) | China | $0.013B | 0.00 |
| IM Cannabis (IMCC) | Canada | $0.012B | 0.00 |
| Flora Growth (FLGC) | United States | $0.012B | 0.00 |
| Sharps Technology (STSS) | United States | $0.011B | 0.00 |
| Innovative Eyewear (LUCY) | United States | $0.007B | 0.00 |
| GlucoTrack (GCTK) | United States | $0.004B | 0.00 |
| Akanda (AKAN) | Canada | $0.002B | 0.00 |
| InterCure (INCR) | Israel | $0.000B | 0.00 |
| InVivo Therapeutics Holdings (NVIVQ) | United States | $0.000B | 0.00 |